Immunosuppressive Strategies in Kidney Xenotransplantation with an Emphasis on Complement Inhibition

Kidney xenotransplantation has reemerged as a viable therapeutic strategy to address the global shortage of donor organs, driven by substantial advances in porcine genetic engineering and immunomodulatory therapies. Clinical experiences in brain-dead decedents and, more recently, in living recipients have demonstrated that genetically modified pig kidneys can provide life-sustaining renal function in humans, marking a pivotal milestone in the field.

Elimination of major carbohydrate xenoantigens, particularly through GGTA1 deletion, has effectively abrogated hyperacute rejection, enabling short- to intermediate-term xenograft survival. However, emerging data reveal that xenotransplantation elicits a uniquely aggressive and persistent immune response involving both innate and adaptive immunities. Conventional immunosuppressive regimens used in kidney allotransplantation appear insufficient when reduced in intensity and require full-dose application combined with B-cell depletion and costimulation blockade to control preexisting xenoreactive T cells and de novo antibody formation. Complement activation remains a central pathogenic mechanism despite extensive donor genetic modification, with emerging evidence suggesting that sustained control of both terminal and proximal complement activation may be beneficial in selected settings. An additional, unexpected challenge is the development of early and often persistent nephrotic-range proteinuria, which may reflect species-specific glomerular barrier incompatibilities, immune-mediated injury, or both, and may have important implications for graft survival by promoting urinary loss of biologic immunosuppressive agents.

Hyperacute rejection in kidney xenotransplantation has been effectively overcome through targeted genetic modifications of donor pigs. However, xenotransplantation remains characterized by a sustained adaptive and innate immune response and ongoing complement activation, necessitating intensified and multimodal immunosuppression. An additional emerging challenge is early and sometimes persistent nephrotic-range proteinuria, which may compromise graft function and alter the pharmacokinetics of biologic immunosuppressive agents. Future progress will depend on integrated strategies combining genetic engineering, costimulation blockade, and appropriately targeted complement inhibition to achieve long-term xenograft survival.